CERS
CERUS CORP
NASDAQ · Healthcare · Medical - Devices · US
$2.65
−0.38%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.65
From 52W high−19.21%
Volume3.55M
Market cap$534.04M
P/E (TTM)—
P/S (TTM)2.4x
Div yield—
Key dataSep 18, 2026
Open
$2.65
From 52W high
−19.21%
Volume
3.55M
Market cap
$534.04M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
190.9x
P/E (TTM)
—
RSI (14)
48.9
MomentumView details →
1D Return
−0.38%
YTD Return
+26.46%
SummaryUpdated Jun 1, 2026
Cerus Corporation (NASDAQ:CERS) is a biomedical products company founded in 1991 and headquartered in Concord, California. The company went public in 1997 and has spent over three decades developing and commercializing blood safety technologies. Cerus operates as a specialized medical device company focused on pathogen reduction systems for blood transfusions, representing a critical niche within the broader healthcare industry. The company has evolved from a research-stage biotechnology firm into a commercial-stage enterprise with global operations, achieving its first profitable year in 2024 after years of development and market penetration efforts.
Similar companies
Latest newsMore news →
Cerus reported Q2 2026 results showing product revenue growth of 10%, a 7% decrease in operating expenses, and adjusted EBITDA more than tripling year-over-year.33d agoCerus Corporation announced its financial results for the second quarter of 2026.52d agoCerus Corporation entered into a Second Amended and Restated Credit, Security and Guaranty Agreement on June 5, 2026, establishing a secured term loan facility of up to $65.0 million, with $35.0 million drawn at closing to refinance existing debt and $30.0 million available subject to lender approval, plus a secured revolving facility with an initial $30.0 million commitment.105d ago